11 fast-growing small-cap stocks that could get a boost from the Fed's next move

Small-cap stocks, having underperformed large-caps, are positioned for a potential rally driven by anticipated Federal Reserve interest rate cuts, which could alleviate borrowing costs. The S&P Small Cap 600 currently presents a more attractive valuation with a forward P/E of 15.5x versus the S&P 500's 22.7x, while also offering diversification benefits. A screen identified 11 S&P Small Cap 600 companies demonstrating consistent profitability and projected to achieve robust revenue growth, with at least a 14% CAGR through 2027, and largely enjoying strong analyst buy ratings and double-digit upside potential.

Analysis

Small-cap stocks, as represented by the S&P Small Cap 600 (SML), have lagged the large-cap S&P 500 (SPX) but present a compelling investment thesis based on relative valuation and a potential macroeconomic catalyst. An anticipated shift to interest rate cuts by the Federal Reserve could disproportionately benefit smaller, domestically focused firms by reducing borrowing costs, potentially triggering a rally. Currently, the S&P Small Cap 600 trades at a forward P/E ratio of 15.5x, closely aligned with its historical 5- and 10-year averages. This valuation is substantially lower than the S&P 500's 22.7x forward P/E, which represents a 20% and 39% premium to its 10- and 20-year averages, respectively. Small-caps also offer significant diversification away from the concentration risk in large-cap indices, where the top five holdings of the SPDR S&P 500 ETF (SPY) comprise 29% of the fund, compared to just 3.6% for the top five in the Vanguard S&P Small-Cap 600 ETF (VIOO). A disciplined screen of the SML index has identified 11 companies with consistent profitability and high-growth prospects, defined by an expected revenue CAGR of at least 14% through 2027. Standouts from this list, such as Corcept Therapeutics (CORT) with a 41.6% projected sales CAGR and Sterling Infrastructure (STRL), have unanimous "buy" ratings from analysts and significant implied upside potential.

Key Decisions for Investors

• Consider increasing allocation to small-cap equities to capitalize on their relative valuation discount to large-caps and the potential performance tailwind from future Federal Reserve rate cuts.
• Utilize the screened list of 11 high-growth, profitable companies as a starting point for fundamental research, focusing on names with strong analyst consensus and high implied upside like Corcept Therapeutics (CORT), Astrana Health (ASTH), and Harmony Biosciences (HRMY).
• Investors should monitor Federal Reserve communications closely, as the timing of rate cuts is a key catalyst; be prepared for potential short-term market volatility, which could present more favorable entry points for building small-cap positions.